mRNA-based vaccine technology development
CureVac is accelerating vaccine technology development, getting lifesaving and low-cost vaccines to people who need them most.
-
Domain
-
Investment typeDirect equity
-
StatusActive
-
Initial investmentSeries F
-
Partnered in2015
-
Investment leadDavid Rossow
-
HeadquartersGermany
-
Program strategyVaccine Development
More about our work
Our focus
Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.
Investment approach
Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.
Our team
We bring depth of experience to every investment, with a proven track record across sectors and scale.